Journal
NANOMEDICINE
Volume 17, Issue 1, Pages 41-64Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2021-0207
Keywords
breast cancer; metastasis; multidrug resistance; ovarian cancer; siRNA delivery
Ask authors/readers for more resources
Metastasis is a major challenge in cancer therapy, and while siRNA therapeutics show promise in treatment, they may not be sufficient on their own. Combining siRNA with targeting agents or small molecule drugs can enhance therapeutic effectiveness in controlling metastasis.
Metastasis is considered the major cause of unsuccessful cancer therapy. The metastatic development requires tumor cells to leave their initial site, circulate in the blood stream, acclimate to new cellular environments at a remote secondary site and endure there. There are several steps in metastasis, including invasion, intravasation, circulation, extravasation, premetastatic niche formation, micrometastasis and metastatic colonization. siRNA therapeutics are appreciated for their usefulness in treatment of cancer metastasis. However, siRNA therapy as a single therapy may not be a sufficient option for control of metastasis. By combining siRNA with targeting, functional agents or small molecule drugs have shown potential effects that enhance therapeutic effectiveness. This review addresses multidrug resistance and metastasis in breast and ovarian cancers and highlights drug delivery strategies using siRNA therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available